We invite you to share your personal experience living with Grade 2 IDH-mutant glioma, particularly the impact of seizures, whether or not you have experienced any. Your story matters. By taking part, you will be helping to shape better support materials, resources and educational tools for others navigating this diagnosis and their families.

The survey will take approximately 10 minutes to complete.

We will carry out this market research in accordance with the relevant Australian Privacy Principles. The survey is being conducted by METIS Healthcare Research, an independent healthcare market research company. Any information that is presented and subjects discussed are not intended to be promotional. The Personal Information you provide will be used only for the purpose of this survey. Your answers to the questions will be combined with those of other participants, to produce aggregated, de-identified results. The aggregate results of this survey may be used for education, advocacy and publication. If you mention an adverse event or side effect in relation to a Servier product we are obliged to report this to Servier but your identity will remain anonymous.

You do not have to answer every question. You may skip any questions you do not wish to answer. In agreeing to participate, you agree to this Privacy Statement.

If you have any questions or need assistance during the survey, please contact: Sally Hogbin, Director at METIS Healthcare Research, via phone +61 409 394 191 or email sallyhogbin@metisresearch.com.au.